CureVac Form 6-K files EGM voting outcomes, joins BioNTech F-4

Rhea-AI Filing Summary

CureVac N.V. submitted a Form 6-K reporting that it issued a press release on November 25, 2025 announcing the voting results of its extraordinary general meeting of shareholders. The press release, attached as Exhibit 99.1, includes a table showing how shareholders voted on the items presented at the meeting.

The submission also states that the information in this Form 6-K, including the exhibit, is deemed filed and incorporated by reference into BioNTech SE’s registration statement on Form F-4 (File No. 333-289468), becoming part of that registration statement from the filing date unless later superseded.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2025

Commission File Number: 001-39446

CureVac N.V.

(Exact Name of Registrant as Specified in Its Charter)

Friedrich-Miescher-Strasse 15, 72076

Tübingen, Germany

+49 7071 9883 0

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F x           Form 40-F ¨

 Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes ¨           No x

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes ¨           No x

On November 25, 2025, CureVac N.V. (the “Company”) issued a press release announcing the voting results of the Company’s extraordinary general meeting of shareholders, including a table containing tabulations of the votes cast.

The information included in this Form 6-K (including Exhibit 99.1) shall be deemed to be filed and incorporated by reference in BioNTech SE’s registration statement on Form F-4 (File No. 333-289468) and to be part thereof from the date on which this Form 6-K is filed, to the extent not superseded by documents or reports subsequently filed.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	CureVac N.V.
	(Registrant)
Date: November 26, 2025	By:	/s/ Alexander Zehnder
		Chief Executive Officer

EXHIBIT INDEX

EXHIBIT NO.		DESCRIPTION
99.1		CureVac N.V. Press Release dated November 25, 2025

FAQ

What did CureVac N.V. (CVAC) report in this November 2025 Form 6-K?

CureVac N.V. reported that it issued a press release on November 25, 2025 announcing the voting results of its extraordinary general meeting of shareholders, with vote tabulations included in a table.

What is included as Exhibit 99.1 to CureVac N.V.’s Form 6-K?

Exhibit 99.1 is a CureVac N.V. press release dated November 25, 2025 that describes the voting results of the company’s extraordinary general meeting of shareholders and includes detailed vote tabulations.

How does this CureVac (CVAC) Form 6-K relate to BioNTech SE’s Form F-4?

The information in this Form 6-K, including Exhibit 99.1, is deemed filed and incorporated by reference into BioNTech SE’s registration statement on Form F-4 (File No. 333-289468) and forms part of that registration statement from the filing date.

What corporate event at CureVac N.V. is covered by this Form 6-K?

The Form 6-K covers the extraordinary general meeting of shareholders of CureVac N.V. and the announcement of the voting results from that meeting in a press release.

Who signed the CureVac N.V. Form 6-K and in what capacity?

The Form 6-K was signed on behalf of CureVac N.V. by Alexander Zehnder in his capacity as Chief Executive Officer.

Does this CureVac (CVAC) Form 6-K contain detailed financial or earnings data?

This Form 6-K focuses on reporting the voting results of an extraordinary general meeting and the related press release, rather than providing detailed financial or earnings data.